Q4 2010

Source filing unavailable

Q4 2010 · —

derived · Computed from the longer spans the company filed.

Revenue—

Net income—

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived-$7,375,069—

Free Cash Flowderived-$7,705,806—

Same quarter

no prior Q4 2009 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR